Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 9, Status: Authorised | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 16 January 2026 - 16:42

Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 9, Status: Authorised

Link:

https://www.ema.europa.eu/en/medicines/human/EPAR/rystiggo

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters